Citations (66)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Melanie Davies, Sudesna Chatterjee & Kamlesh Khunti. (2016) The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies. Clinical Pharmacology: Advances and Applications 8, pages 61-81.
Read now
Read now
Jochen Seufert. (2015) SGLT2 inhibitors – an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin. Diabetes, Metabolic Syndrome and Obesity 8, pages 543-554.
Read now
Read now
Jaime A. Davidson & Louis Kuritzky. (2014) Sodium Glucose Co-Transporter 2 Inhibitors and Their Mechanism for Improving Glycemia in Patients with Type 2 Diabetes. Postgraduate Medicine 126:6, pages 33-48.
Read now
Read now
Stephen Brunton & Timothy S. Reid. (2014) Canagliflozin, a Sodium Glucose Co-transporter 2 Inhibitor, for the Management of Type 2 Diabetes. Hospital Practice 42:3, pages 96-108.
Read now
Read now
Jean M Whaley, Mark Tirmenstein, Timothy P Reilly, Simon M Poucher, JoAnne Saye, Shamik Parikh & James F List. (2012) Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus. Diabetes, Metabolic Syndrome and Obesity 5, pages 135-148.
Read now
Read now
Articles from other publishers (61)
Harold Edward Bays. (2023) Why does type 2 diabetes mellitus impair weight reduction in patients with obesity? A review. Obesity Pillars 7, pages 100076.
Crossref
Crossref
Xiaoyun Wang, Zhendong Sun, Yurou Gao, Qian S. Liu, Xiaoxi Yang, Jiefeng Liang, Jing Ren, Zhihua Ren, Qunfang Zhou & Guibin Jiang. (2023) 3-tert-Butyl-4-hydroxyanisole perturbs renal lipid metabolism in vitro by targeting androgen receptor-regulated de novo lipogenesis. Ecotoxicology and Environmental Safety 258, pages 114979.
Crossref
Crossref
Harold Edward Bays, Shagun Bindlish & Tiffany Lowe Clayton. (2023) Obesity, diabetes mellitus, and cardiometabolic risk: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2023. Obesity Pillars 5, pages 100056.
Crossref
Crossref
Yanbei Duo, Junxiang Gao, Tao Yuan & Weigang Zhao. (2023) Effect of sodium‐glucose cotransporter 2 inhibitors on the rate of decline in kidney function: A systematic review and meta‐analysis. Journal of Diabetes 15:1, pages 58-70.
Crossref
Crossref
Harold E. Bays, Angela Fitch, Sandra Christensen, Karli Burridge & Justin Tondt. (2022) Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. Obesity Pillars 2, pages 100018.
Crossref
Crossref
Justin Tondt & Harold Edward Bays. (2022) Concomitant medications, functional foods, and supplements: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. Obesity Pillars 2, pages 100017.
Crossref
Crossref
Harold E Bays, Anandita Agarwala, Charles German, Priyanka Satish, Adedapo Iluyomade, Ramzi Dudum, Aarti Thakkar, Mahmoud Al Rifai, Anurag Mehta, Aneesha Thobani, Yousif Al-Saiegh, Adam J Nelson, Samip Sheth & Peter P. Toth. (2022) Ten things to know about ten cardiovascular disease risk factors – 2022. American Journal of Preventive Cardiology 10, pages 100342.
Crossref
Crossref
Mudassar Ahemadkhan PathanAjay Kshirsagar. (2022) Stability Indicating HPLC Method Development and Validation for Simultaneous Estimation of Metformin and Empagliflozin in Bulk and Pharmaceutical Dosage Form. Research Journal of Pharmacy and Technology, pages 830-836.
Crossref
Crossref
Zhongyu Han, Kuai Ma, Hongxia Tao, Hongli Liu, Jiong Zhang, Xiyalatu Sai, Yunlong Li, Mingxuan Chi, Qing Nian, Linjiang Song & Chi Liu. (2022) A Deep Insight Into Regulatory T Cell Metabolism in Renal Disease: Facts and Perspectives. Frontiers in Immunology 13.
Crossref
Crossref
O. Y. Sukhareva, Z. T. Zuraeva & M. S. Shamhalova. (2022) Gliflozins position update in the treatment algorithms for patients with type 2 diabetes mellitus and chronic kidney disease: new pathogenetic mechanisms and data from subanalyses of the large randomised control trails. Diabetes mellitus 24:6, pages 553-564.
Crossref
Crossref
Samuel Seidu, Setor K Kunutsor, Pinar Topsever & Kamlesh Khunti. (2021) Benefits and harms of sodium‐glucose co‐transporter‐2 inhibitors (SGLT2‐I) and renin–angiotensin–aldosterone system inhibitors (RAAS‐I) versus SGLT2‐Is alone in patients with type 2 diabetes: A systematic review and meta‐analysis of randomized controlled trials. Endocrinology, Diabetes & Metabolism 5:1.
Crossref
Crossref
Chern-En Chiang, Kwo-Chang Ueng, Ting-Hsing Chao, Tsung-Hsien Lin, Yih-Jer Wu, Kang-Ling Wang, Shih-Hsien Sung, Hung-I Yeh, Yi-Heng Li, Ping-Yen Liu, Kuan-Cheng Chang, Kou-Gi Shyu, Jin-Long Huang, Cheng-Dao Tsai, Huei-Fong Hung, Ming-En Liu, Tze-Fan Chao, Shu-Meng Cheng, Hao-Min Cheng, Pao-Hsien Chu, Wei-Hsian Yin, Yen-Wen Wu, Wen-Jone Chen, Wen-Ter Lai, Shing-Jong Lin, San-Jou Yeh, Juey-Jen Hwang & Charles Jia-Yin Hou. (2021) 2021 Consensus Pathway of the Taiwan Society of Cardiology on Novel Therapy for Type 2 Diabetes. JACC: Asia 1:2, pages 129-146.
Crossref
Crossref
Michele Provenzano, Maria Chiara Pelle, Isabella Zaffina, Bruno Tassone, Roberta Pujia, Marco Ricchio, Raffaele Serra, Angela Sciacqua, Ashour Michael, Michele Andreucci & Franco Arturi. (2021) Sodium-Glucose Co-transporter-2 Inhibitors and Nephroprotection in Diabetic Patients: More Than a Challenge. Frontiers in Medicine 8.
Crossref
Crossref
Harold E. Bays, Pam R. Taub, Elizabeth Epstein, Erin D. Michos, Richard A. Ferraro, Alison L. Bailey, Heval M. Kelli, Keith C. Ferdinand, Melvin R. Echols, Howard Weintraub, John Bostrom, Heather M. Johnson, Kara K. Hoppe, Michael D. Shapiro, Charles A. German, Salim S. Virani, Aliza Hussain, Christie M. Ballantyne, Ali M. Agha & Peter P. Toth. (2021) Ten things to know about ten cardiovascular disease risk factors. American Journal of Preventive Cardiology 5, pages 100149.
Crossref
Crossref
Masafumi Fukuda, Masakazu Nabeta, Takanori Muta, Kei Fukami & Osamu Takasu. (2020) Euglycemic diabetic ketoacidosis caused by canagliflozin: a case report. International Journal of Emergency Medicine 13:1.
Crossref
Crossref
Karen E. Elkind-Hirsch, Ericka Seidemann & Renee Harris. (2020) A randomized trial of dapagliflozin and metformin, alone and combined, in overweight women after gestational diabetes mellitus. American Journal of Obstetrics & Gynecology MFM 2:3, pages 100139.
Crossref
Crossref
Chern-En Chiang, Kwo-Chang Ueng, Ting-Hsing Chao, Tsung-Hsien Lin, Yih-Jer Wu, Kang-Ling Wang, Shih-Hsien Sung, Hung-I Yeh, Yi-Heng Li, Ping-Yen Liu, Kuan-Cheng Chang, Kou-Gi Shyu, Jin-Long Huang, Cheng-Dao Tsai, Huei-Fong Hung, Ming-En Liu, Tze-Fan Chao, Shu-Meng Cheng, Hao-Min Cheng, Pao-Hsien Chu, Wei-Hsian Yin, Yen-Wen Wu, Wen-Jone Chen, Wen-Ter Lai, Shing-Jong Lin, San-Jou Yeh & Juey-Jen Hwang. (2020) 2020 Consensus of Taiwan Society of Cardiology on the pharmacological management of patients with type 2 diabetes and cardiovascular diseases. Journal of the Chinese Medical Association 83:7, pages 587-621.
Crossref
Crossref
Harold E. Bays, Plamen Kozlovski, Qing Shao, Pieter Proot & Deborah Keefe. (2020) Licogliflozin, a Novel SGLT1 and 2 Inhibitor: Body Weight Effects in a Randomized Trial in Adults with Overweight or Obesity. Obesity 28:5, pages 870-881.
Crossref
Crossref
Chern-En Chiang, Kang-Ling Wang, Hao-Min Cheng, Shih-Hsien Sung & Tze-Fan Chao. (2020) Second revolution in cardiovascular prevention. Journal of the Chinese Medical Association 83:4, pages 327-336.
Crossref
Crossref
Anja Schork, Janine Saynisch, Andreas Vosseler, Benjamin Assad Jaghutriz, Nils Heyne, Andreas Peter, Hans-Ulrich Häring, Norbert Stefan, Andreas Fritsche & Ferruh Artunc. (2019) Effect of SGLT2 inhibitors on body composition, fluid status and renin–angiotensin–aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy. Cardiovascular Diabetology 18:1.
Crossref
Crossref
Milad Ashrafizadeh, Habib Yaribeygi, Stephen L. Atkin & Amirhossein Sahebkar. (2019) Effects of newly introduced antidiabetic drugs on autophagy. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 13:4, pages 2445-2449.
Crossref
Crossref
Chih-Chao Yang, Yen-Ta Chen, Christopher Glenn Wallace, Kuan-Hung Chen, Ben-Chung Cheng, Pei-Hsun Sung, Yi-Chen Li, Sheung-Fat Ko, Hsueh-Wen Chang & Hon-Kan Yip. (2019) Early administration of empagliflozin preserved heart function in cardiorenal syndrome in rat. Biomedicine & Pharmacotherapy 109, pages 658-670.
Crossref
Crossref
Samuel Seidu, Setor K. Kunutsor, Xavier Cos, Syed Gillani & Kamlesh Khunti. (2018) SGLT2 inhibitors and renal outcomes in type 2 diabetes with or without renal impairment: A systematic review and meta-analysis. Primary Care Diabetes 12:3, pages 265-283.
Crossref
Crossref
Anna Sadurní, Gerald Kehr, Marie Ahlqvist, Johan Wernevik, Helena Peilot Sjögren, Cecilia Kankkonen, Laurent Knerr & Ryan Gilmour. (2018) Fluorine-Directed Glycosylation Enables the Stereocontrolled Synthesis of Selective SGLT2 Inhibitors for Type II Diabetes. Chemistry - A European Journal 24:12, pages 2832-2836.
Crossref
Crossref
Valerie Azzopardi Coppenrath & Tasmina Hydery. (2017) Dapagliflozin/Saxagliptin Fixed-Dose Tablets: A New Sodium-Glucose Cotransporter 2 and Dipeptidyl Peptidase 4 Combination for the Treatment of Type 2 Diabetes. Annals of Pharmacotherapy 52:1, pages 78-85.
Crossref
Crossref
Ewa Otto-Buczkowska & Natalia Jainta. (2017) Pharmacological Treatment in Diabetes Mellitus Type 1 – Insulin and What Else?. International Journal of Endocrinology and Metabolism 16:1.
Crossref
Crossref
Luca Di Lullo, Michela Mangano, Claudio Ronco, Vincenzo Barbera, Antonio De Pascalis, Antonio Bellasi, Domenico Russo, Biagio Di Iorio & Mario Cozzolino. (2017) The treatment of type 2 diabetes mellitus in patients with chronic kidney disease: What to expect from new oral hypoglycemic agents. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 11, pages S295-S305.
Crossref
Crossref
Krit Jaikumkao, Anchalee Pongchaidecha, Varanuj Chatsudthipong, Siriporn C. Chattipakorn, Nipon Chattipakorn & Anusorn Lungkaphin. (2017) The roles of sodium-glucose cotransporter 2 inhibitors in preventing kidney injury in diabetes. Biomedicine & Pharmacotherapy 94, pages 176-187.
Crossref
Crossref
Manisha Gupte, Prachi Umbarkar & Hind Lal. (2017) Mechanistic Insights of Empagliflozin-Mediated Cardiac Benefits: Nearing the Starting Line. Cardiovascular Drugs and Therapy 31:3, pages 229-232.
Crossref
Crossref
Paresh Dandona & Ajay Chaudhuri. (2017) Sodium-glucose co-transporter 2 inhibitors for type 2 diabetes mellitus: An overview for the primary care physician. International Journal of Clinical Practice 71:5, pages e12937.
Crossref
Crossref
Harold E. Bays, Peter Sartipy, John Xu, Carl David Sjöström & James A. Underberg. (2017) Dapagliflozin in patients with type II diabetes mellitus, with and without elevated triglyceride and reduced high-density lipoprotein cholesterol levels. Journal of Clinical Lipidology 11:2, pages 450-458.e1.
Crossref
Crossref
Xiao-Dan Yue, Jing-Yu Wang, Xin-Rong Zhang, Ju-Hong Yang, Chun-Yan Shan, Miao-Yan Zheng, Hui-Zhu Ren, Yi Zhang, Shao-Hua Yang, Zhen-Hong Guo, Bai Chang & Bao-Cheng Chang. (2017) Characteristics and Impact Factors of Renal Threshold for Glucose Excretion in Patients with Type 2 Diabetes Mellitus. Journal of Korean Medical Science 32:4, pages 621.
Crossref
Crossref
S. Mishra, A.S. Singh, N. Mishra, H. Pandey & V.K. Tiwari. 2017. Discovery and Development of Antidiabetic Agents from Natural Products. Discovery and Development of Antidiabetic Agents from Natural Products
147
183
.
G. Bebernitz. 2017. Comprehensive Medicinal Chemistry III. Comprehensive Medicinal Chemistry III
491
511
.
Nellowe Candelario & Jedrzej Wykretowicz. (2016) The DKA that wasn't: a case of euglycemic diabetic ketoacidosis due to empagliflozin. Oxford Medical Case Reports 2016:7, pages 144-146.
Crossref
Crossref
Harold Bays, Shanu N. Kothari, Dan E. Azagury, John M. Morton, Ninh T. Nguyen, Peter H. Jones, Terry A. Jacobson, David E. Cohen, Carl Orringer, Eric C. Westman, Deborah B. Horn, Wendy Scinta & Craig Primack. (2016) Lipids and bariatric procedures Part 2 of 2: scientific statement from the American Society for Metabolic and Bariatric Surgery (ASMBS), the National Lipid Association (NLA), and Obesity Medicine Association (OMA). Surgery for Obesity and Related Diseases 12:3, pages 468-495.
Crossref
Crossref
Norm Rosenthal, Gary Meininger, Kirk Ways, David Polidori, Mehul Desai, Rong Qiu, Maria Alba, Frank Vercruysse, Dainius Balis, Wayne Shaw, Robert Edwards, Scott Bull, Nicholas Di Prospero, Sue Sha, Paul Rothenberg, William Canovatchel & Keith Demarest. (2015) Canagliflozin: a sodium glucose co‐transporter 2 inhibitor for the treatment of type 2 diabetes mellitus. Annals of the New York Academy of Sciences 1358:1, pages 28-43.
Crossref
Crossref
Madhu Babu Tatina, Anil Kumar Kusunuru & Debaraj Mukherjee. (2015)
Organo-zinc Promoted Diastereoselective
C
-Arylation of 1,2-Anhydrosugars from Arylboronic Acids
. Organic Letters 17:18, pages 4624-4627.
Crossref
Crossref
Julian P. Henschke, Chen-Wei Lin, Ping-Yu Wu, Wen-Shing Tsao, Jyh-Hsiung Liao & Pei-Chen Chiang. (2015)
β-Selective
C
-Arylation of Diisobutylaluminum Hydride Modified 1,6-Anhydroglucose: Synthesis of Canagliflozin without Recourse to Conventional Protecting Groups
. The Journal of Organic Chemistry 80:10, pages 5189-5195.
Crossref
Crossref
Julian P. Henschke, Ping-Yu Wu, Chen-Wei Lin, Shi-Feng Chen, Pei-Chen Chiang & Chi-Nung Hsiao. (2015)
β-Selective
C
-Arylation of Silyl Protected 1,6-Anhydroglucose with Arylalanes: The Synthesis of SGLT2 Inhibitors
. The Journal of Organic Chemistry 80:4, pages 2295-2309.
Crossref
Crossref
Bassam M. Ayoub. (2015) UPLC simultaneous determination of empagliflozin, linagliptin and metformin. RSC Advances 5:116, pages 95703-95709.
Crossref
Crossref
J. Girard. (2015) M?canisme d?action des inhibiteurs du cotransporteur sodiumglucose de type 2 (SGLT2). M?decine des Maladies M?taboliques 9:1, pages S10-S16.
Crossref
Crossref
S. Sha, D. Polidori, T. Heise, J. Natarajan, K. Farrell, S.-S. Wang, D. Sica, P. Rothenberg & L. Plum-Mörschel. (2014) Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism 16:11, pages 1087-1095.
Crossref
Crossref
John P.H. Wilding. (2014) The role of the kidneys in glucose homeostasis in type 2 diabetes: Clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitors. Metabolism 63:10, pages 1228-1237.
Crossref
Crossref
Matt Hrapchak, Bachir Latli, Xiao-Jun Wang, Heewon Lee, Scot Campbell, Jinhua J. Song & Chris H. Senanayake. (2014) Synthesis of empagliflozin, a novel and selective sodium-glucose co-transporter-2 inhibitor, labeled with carbon-14 and carbon-13. Journal of Labelled Compounds and Radiopharmaceuticals 57:12, pages 687-694.
Crossref
Crossref
Sue Sha, Damayanthi Devineni, Atalanta Ghosh, David Polidori, Marcus Hompesch, Sabine Arnolds, Linda Morrow, Heike Spitzer, Keith Demarest & Paul Rothenberg. (2014) Pharmacodynamic Effects of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, from a Randomized Study in Patients with Type 2 Diabetes. PLoS ONE 9:8, pages e105638.
Crossref
Crossref
Harold E. Bays, Richard Weinstein, Gordon Law & William Canovatchel. (2013) Canagliflozin: Effects in overweight and obese subjects without diabetes mellitus. Obesity 22:4, pages 1042-1049.
Crossref
Crossref
Chang Hee JungJung Eun JangJoong-Yeol Park. (2014) A Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2 Inhibitor. Diabetes & Metabolism Journal 38:4, pages 261.
Crossref
Crossref
Harold Bays. (2013) Sodium Glucose Co-transporter Type 2 (SGLT2) Inhibitors: Targeting the Kidney to Improve Glycemic Control in Diabetes Mellitus. Diabetes Therapy 4:2, pages 195-220.
Crossref
Crossref
Mark Tirmenstein, Thomas E. Dorr, Evan B. Janovitz, Deborah Hagan, Lynn M. Abell, Joelle M. Onorato, Jean M. Whaley, Michael J. Graziano & Timothy P. Reilly. (2013) Nonclinical Toxicology Assessments Support the Chronic Safety of Dapagliflozin, a First-in-Class Sodium-Glucose Cotransporter 2 Inhibitor. International Journal of Toxicology 32:5, pages 336-350.
Crossref
Crossref
J. Girard. (2013) Le rôle du rein dans l’homéostasie du glucose. Médecine des Maladies Métaboliques 7:1, pages 41-48.
Crossref
Crossref
James F. Sigafoos, Gary D. Bowers, Stephen Castellino, Amanda G. Culp, David S. Wagner, Melinda J. Reese, Joan E. Humphreys, Elizabeth K. Hussey, Robin L. O'Connor Semmes, Anita Kapur, Wenli Tao, Robert L. Dobbins & Joseph W. Polli. (2012) Assessment of the Drug Interaction Risk for Remogliflozin Etabonate, a Sodium-Dependent Glucose Cotransporter-2 Inhibitor: Evidence from In Vitro, Human Mass Balance, and Ketoconazole Interaction Studies. Drug Metabolism and Disposition 40:11, pages 2090-2101.
Crossref
Crossref
Harold E. Bays. (2012) Adiposopathy, Diabetes Mellitus, and Primary Prevention of Atherosclerotic Coronary Artery Disease: Treating “Sick Fat” Through Improving Fat Function with Antidiabetes Therapies. The American Journal of Cardiology 110:9, pages 4B-12B.
Crossref
Crossref
D. Devineni, L. Morrow, M. Hompesch, D. Skee, A. Vandebosch, J. Murphy, K. Ways & S. Schwartz. (2012) Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes, Obesity and Metabolism 14:6, pages 539-545.
Crossref
Crossref
Rolf Grempler, Robert Augustin, Stefanie Froehner, Tobias Hildebrandt, Eric Simon, Michael Mark & Peter Eickelmann. (2011) Functional characterisation of human SGLT‐5 as a novel kidney‐specific sodium‐dependent sugar transporter. FEBS Letters 586:3, pages 248-253.
Crossref
Crossref
L. Thomas, R. Grempler, M. Eckhardt, F. Himmelsbach, A. Sauer, T. Klein, P. Eickelmann & M. Mark. (2011) Long‐term treatment with empagliflozin, a novel, potent and selective SGLT‐2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats. Diabetes, Obesity and Metabolism 14:1, pages 94-96.
Crossref
Crossref
Paolo Cavallo Perin & Paolo Fornengo. (2011) New oral antidiabetic agents. Internal and Emergency Medicine 6:S1, pages 135-138.
Crossref
Crossref
Masayuki Isaji. (2011) SGLT2 inhibitors: molecular design and potential differences in effect. Kidney International 79, pages S14-S19.
Crossref
Crossref
Clifford J. Bailey. (2011) Renal glucose reabsorption inhibitors to treat diabetes. Trends in Pharmacological Sciences 32:2, pages 63-71.
Crossref
Crossref
F. R. Macdonald, J. E. Peel, H. B. Jones, R. M. Mayers, L. Westgate, J. M. Whaley & S. M. Poucher. (2010) The novel sodium glucose transporter 2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats. Diabetes, Obesity and Metabolism 12:11, pages 1004-1012.
Crossref
Crossref
Huiqiang Zhou, Dana P. Danger, Steven T. Dock, Lora Hawley, Shane G. Roller, Chari D. Smith & Anthony L. Handlon. (2010)
Synthesis and SAR of Benzisothiazole- and Indolizine-β-
d
-glucopyranoside Inhibitors of SGLT2
. ACS Medicinal Chemistry Letters 1:1, pages 19-23.
Crossref
Crossref